ANRO vs CNTB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CNTB Captures Institutional Edge (2โ2 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Connect Biopharma Holdings Limited Ordinary Shares (CNTB) driven by superior Valuation, Options & Structure while ANRO counters with relative strength in Growth & Margin, Momentum & Technical. Fundamentally, ANRO trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CNTB at 0.8x Forward P/E and -2384.5% operating margin (+5666.7% YoY). In options structure, ANRO sits in BREAKDOWN (8th %ile IV; Dealer Gamma Walls on Pro) against CNTB sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ANRO | CNTB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $1.2B | $42.6M | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | N/M | 0.8x | Lower Multiple | CNTB |
| Forward P/E Ratio Valuation | N/M | 0.8x | Lower Multiple | CNTB |
| Revenue Growth (YoY) Growth | +0.0% | +5666.7% | Higher Growth | CNTB |
| Operating Margin (TTM) Profitability | 0.0% | -2384.5% | Higher Margin | ANRO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -46.7% | -140.5% | Higher ROE | ANRO |
| 52-Week Range Position Momentum | 54% ($11โ$37) | 1% ($1โ$4) | Stronger Trend | ANRO |
| Beta / 30D Volatility Risk Regime | 2.03ฮฒ ยท 94% Vol | 0.92ฮฒ ยท 68% Vol | Lower Realized Risk | CNTB |
| Unified Institutional Score Composite Signal | 34.3 / 100 (SELL) | 41.0 / 100 (SELL) | Higher Composite | CNTB |